Global Leading Market Research Publisher QYResearch announces the release of its latest report “Veterinary Antiparasitic Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Veterinary Antiparasitic Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Veterinary Antiparasitic Drugs was estimated to be worth US5,800millionin2025andisprojectedtoreachUS5,800millionin2025andisprojectedtoreachUS 7,900 million, growing at a CAGR of 4.5% from 2026 to 2032. Veterinary antiparasitic drugs are pharmaceutical agents used to prevent and treat parasitic infections in livestock (cattle, sheep, pigs, poultry, horses), companion animals (dogs, cats), and zoo animals. Parasitic infections (endoparasites: roundworms, tapeworms, flukes; ectoparasites: ticks, mites, fleas, lice) are highly prevalent in the livestock industry (80-95% of herds in tropical/subtropical regions), causing significant economic losses: reduced weight gain (10-30%), decreased milk production (5-20%), lower fertility (10-25%), increased mortality (5-15%), and hide/skin damage. Drug classes include antihelmintics (nematodes, cestodes, trematodes: benzimidazoles, macrocyclic lactones, imidazothiazoles, salicylanilides) and antiprotozoals (coccidia, Babesia, Theileria, Trypanosoma, Giardia: ionophores, triazines, quinolones). The market is driven by global livestock production growth (increasing meat/milk demand 2-3% CAGR), rising companion animal ownership (parasite prevention), anthelmintic resistance (need for new drug classes/combinations), and regulatory standards (food safety, residue limits). Industry pain points include drug resistance (1-30% efficacy loss, 5-10 years after launch), residue violations (withdrawal periods, 0.5-2% non-compliance), and off-label use (zoo animals, minor species).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5973719/veterinary-antiparasitic-drugs
1. Recent Industry Data and Livestock Health Trends
Between Q4 2025 and Q2 2026, the veterinary antiparasitic drugs sector has witnessed steady growth driven by livestock production expansion, parasite prevalence, and anthelmintic resistance. In January 2026, the global animal health market reached 45B(antiparasitics1345B(antiparasitics135.8B), growing 5% YoY. According to animal health data, antihelmintics hold 65% market share (endoparasites), antiprotozoals 35% (coccidia, babesia, trypanosomiasis). Global cattle population 1.5B head (2025), sheep/goats 2.2B, pigs 1.0B, poultry 25B. Parasite prevalence: nematodes 80-95% (grazing livestock), coccidia 50-80% (poultry, calves), ticks 30-60% (tropical/subtropical). Anthelmintic resistance reported in 50+ countries (Haemonchus contortus, Cooperia, Ostertagia, Teladorsagia), 10-50% efficacy loss. EU’s Veterinary Medicines Regulation (March 2026) limits prophylactic use (metaphylaxis), promotes targeted selective treatment (TST). WHO/FAO/OIE Codex Alimentarius (April 2026) updates maximum residue limits (MRLs) for antiparasitics in food products (meat, milk, eggs).
2. User Case – Antihelmintics vs. Antiprotozoal Drugs
A comprehensive veterinary parasitology study (n=650 livestock farms, veterinary practices across 15 countries) revealed distinct drug requirements:
- Antihelmintics (65% market share, 4% CAGR): Benzimidazoles (albendazole, fenbendazole, 10-20mg/kg, wide spectrum, 5-10 day withdrawal). Macrocyclic lactones (ivermectin, doramectin, eprinomectin, 0.2mg/kg, long-acting (28-42 days), 14-35 day withdrawal). Imidazothiazoles (levamisole, 5-10mg/kg). Salicylanilides (closantel, rafoxanide, 5-10mg/kg, fluke-specific). Used for nematodes (roundworms), cestodes (tapeworms), trematodes (flukes). Cost $0.50-5 per dose. Growing at 4% CAGR.
- Antiprotozoals (35% market share, 5.5% CAGR): Ionophores (monensin, lasalocid, 50-200g/ton feed, coccidiostat, growth promoter). Triazines (toltrazuril, diclazuril, 10-20mg/kg, coccidia, 0-10 day withdrawal). Quinolones (buparvaquone, imidocarb, 1-5mg/kg, Babesia, Theileria). Used for coccidiosis (poultry, calves, lambs, piglets), babesiosis (cattle, horses), theileriosis (cattle), trypanosomiasis (cattle, camel). Cost $1-20 per dose. Growing at 5.5% CAGR.
Case Example – Cattle Nematode Control (Brazil, 200M head): Brazilian beef cattle (extensive grazing, tropical climate, Haemonchus contortus prevalent) use macrocyclic lactones (ivermectin long-acting, 28-42 day protection, 2/dose,2doses/year).Challenge:anthelminticresistance(302/dose,2doses/year).Challenge:anthelminticresistance(303/dose), efficacy restored to 90%.
Case Example – Poultry Coccidiosis (US, 9B broilers/year): US broiler industry uses ionophores (monensin, lasalocid, 100g/ton feed, $0.05/bird) for coccidiosis prevention. Challenge: ionophore resistance (10-20% efficacy loss, 5-10 years post-launch). Rotation program (ionophores ↔ triazines ↔ synthetic chemicals), resistance managed.
Case Example – Companion Animal Parasite Prevention (US, 80M dogs): Heartworm prevention (Dirofilaria immitis) uses macrocyclic lactones (ivermectin, milbemycin, monthly chewable, 10−20/dose,12doses/year).Flea/tickprevention(isoxazolines,fluralaner,12−weekchewable,10−20/dose,12doses/year).Flea/tickprevention(isoxazolines,fluralaner,12−weekchewable,60-80/dose, 4 doses/year). Challenge: product counterfeiting (online, 5-10% of market). Serialization (QR code, tamper-evident packaging).
3. Technical Differentiation and Manufacturing Complexity
Veterinary antiparasitic drugs involve active pharmaceutical ingredients (APIs), formulations, and regulatory compliance:
- API classes: Benzimidazoles (albendazole, fenbendazole, oxfendazole). Macrocyclic lactones (ivermectin, doramectin, eprinomectin, moxidectin). Imidazothiazoles (levamisole). Salicylanilides (closantel, rafoxanide). Ionophores (monensin, lasalocid, salinomycin). Triazines (toltrazuril, diclazuril). Quinolones (buparvaquone, imidocarb).
- Formulations: Oral (drench, paste, bolus, tablet). Injectable (subcutaneous, intramuscular). Topical (pour-on, spot-on). Feed additive (premix, pellet, crumble). Long-acting (injectable LA, 28-42 days). Combination (2-3 active ingredients, broad spectrum, resistance management).
- Resistance management: Rotation (alternate drug classes, every 6-12 months). Combination (multiple active ingredients, same dose). Targeted selective treatment (TST, treat only animals with high fecal egg count, 20-30% of herd). Refugia (leave 10-20% untreated, susceptible gene pool).
- Regulatory compliance: FDA (US) NADA (new animal drug application), CVM. EMA (EU) MRLs (maximum residue limits), withdrawal periods (0-60 days). China MARA (Ministry of Agriculture and Rural Affairs). Codex Alimentarius (international MRLs). GMP (good manufacturing practice). VICH (harmonized guidelines). Pharmacovigilance (adverse event reporting).
- Quality control: API purity (99-102%). Stability (shelf life 24-36 months). Bioequivalence (generic vs. brand). Residue testing (meat, milk, eggs, liver, kidney, fat, honey). Antimicrobial resistance (AMR) surveillance.
Exclusive Observation – Antihelmintics vs. Antiprotozoals: Antihelmintics (65% share, 4% CAGR, broad spectrum, resistance pressure, mature market). Antiprotozoals (35% share, 5.5% CAGR, coccidia, babesia, theileriosis, trypanosomiasis, emerging market, higher growth). Global leaders (Boehringer Ingelheim, Merck KGaA, Zoetis, Elanco, Ceva) dominate antiparasitics, margins 20-30%. Indian/Chinese manufacturers (Cadila Pharmaceuticals, Watson International, Vivaldis, Glenmark, Weefsel, Meiji, Biowet, HPRA, Medinfar, VET-AGRO, Mobedco, VIC, Vetsintez) have scaled rapidly (40-45% of global API volume) with cost advantage 30-50% lower, but lower regulatory compliance (FDA/EMA approvals), less pharmacovigilance. As anthelmintic resistance spreads (50+ countries, 10-50% efficacy loss), demand for new drug classes (amino-acetonitrile derivatives (AAD), spiroindoles, cyclooctadepsipeptides) and combination products (5-10% CAGR) will grow. Targeted selective treatment (TST) reduces drug use 50-70%, delays resistance, requires rapid diagnostic tests (FEC, FAMACHA, smartphone apps).
4. Competitive Landscape and Market Share Dynamics
Key players: Boehringer Ingelheim (18% share – Germany, cattle, swine, poultry), Merck KGaA (15% – Germany, companion animal), Zoetis (12% – US, livestock), Elanco (10% – US), Ceva (8% – France), others (37% – Weefsel Pharma, Meiji Group, Biowet, HPRA, Medinfar Sorologico, VET-AGRO, Mobedco, VIC, Vetsintez, Cadila, Watson, Vivaldis, Glenmark).
Segment by Drug Type: Antihelmintics (65% market share), Antiprotozoals (35%, fastest-growing 5.5% CAGR for coccidiosis/babesiosis/theileriosis).
Segment by End-User: Farm (85% – cattle, sheep, pigs, poultry, goats, horses), Zoo (10% – exotic animals, wildlife conservation), Others (5% – companion animals, laboratory animals, aquaculture).
5. Strategic Forecast 2026-2032
We project the global veterinary antiparasitic drugs market will reach 7,900millionby2032(4.57,900millionby2032(4.55.50-6.50/dose (combination premium offset by generic commoditization). Key drivers:
- Livestock production growth (meat, milk, eggs): Global meat consumption 360M tons (2025) → 400M tons (2032). Milk 900M tons → 1,000M tons. Eggs 80M tons → 95M tons. Antiparasitic drugs essential for productivity (weight gain +10-30%, milk +5-20%, fertility +10-25%).
- Anthelmintic resistance (emergence, spread): 50+ countries, 10-50% efficacy loss. Demand for new drug classes (AAD, spiroindoles, cyclooctadepsipeptides) and combination products (5-10% CAGR).
- Parasite prevalence (tropical/subtropical, climate change): Expanding geographic range (ticks, flies, mosquitoes, snails). Vector-borne diseases (babesiosis, theileriosis, trypanosomiasis) increasing.
- Targeted selective treatment (TST), reduce drug use 50-70%: Requires rapid diagnostic tests (FEC, FAMACHA, smartphone apps). TST adoption 10-20% (2025) → 30-50% (2032), delaying resistance.
Risks include drug resistance (1-30% efficacy loss, 5-10 years after launch), residue violations (withdrawal periods, 0.5-2% non-compliance, trade barriers), and off-label use (zoo animals, minor species, extrapolation from major species). Manufacturers investing in combination products (5-10% CAGR), new drug classes (AAD, spiroindoles, cyclooctadepsipeptides, 5-8% CAGR), and rapid diagnostic tests (FEC, FAMACHA, smartphone, 10-12% CAGR) will capture share through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
